Hosam Mohamed-
Cost-minimization analysis
- to choose the least costly alternative among interventions with equivalent outcomes
-
healthcare providers, decision makers
Who uses the data from a Cost-Minimization analysis? (2)
-
a
Which of the following is considered a partial economic evaluation/ NOT a full economic analysis?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
b
Which economic analysis assumes equivalent outcomes?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
study design, power of test/sample size, statistical test
What data is important for cost-minimization analysis (CMA)? (3)
-
b
Which economic analysis would most likely require the use of the orange book?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
false
Disimilar adverse effects have no impact on effectiveness and cost. T/F?
-
time-motion analysis
- a standard analytic procedure for determining the time and energy spent in activities over a period of time.
-
cost-benefit analysis (CBA)
•assesses whether the outcomes (benefits) outweigh the inputs (costs) of a program or intervention
-
straightforward, data availability
What are advantages associated with the Human Capital approach? (2)
-
value of future earnings
In the Human Capital approach, value of an intervention can be assessed in terms of the present _____________
-
chronic; acute
Yearly wage rate is best to calculate ________ conditions, while Daily wage rate is best to calculate _______ conditions.
-
value of health benefits equal the economic productivity that those values permit; Value of intervention can be assessed in terms of present value of future earnings
What does the Human capital approach tell us? (2)
-
unethical, biased, earnings don't necessarily equal work, doesn't value pain/suffering
What are disadvantages associated with the Human Capital approach? (4)
-
a
ONLY measures indirect costs/benefits.
a) Human Capital approach
b) Willingness to pay
-
b
Measures BOTH indirect & Intangible costs/benefits.
a) Human Capital approach
b) Willingness to pay
-
hypothetical nature, may feel need to respond in certain way
What are disadvantages associated with WTP method? (2)
-
c
Which pharmacoeconomic analysis can determine whether a goal is worth achieving or not?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
d
Which pharmacoeconomic analysis can ONLY give you the price of achieving a health goal?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
alternatives have a common effect and measured in a natural unit
Cost Effective analysis is used when ________.
-
cost-effective intervention
-outcome worth its corresponding cost relative to competing alternatives
-
intermediate outcome
-measurable effects of a disease or its treatment that are proved to be an indicator of the long-term, final outcome
-i.e. lab measures, disease markers
-
primary outcome
-clinical events
-
false
The intermediate outcome has no value or clinical significance alone. T/F?
-
TC1-TC2/ E1 - E2
ICER formula?
-
more effective and less costly
A new treatment dominates when it is
-
new treatment is more costly and less effective
An existing treatment dominates when
-
Cost-effective analysis (CEA)
- compares relevant costs and consequences of competing drug regiments and interventions.
-
Health-related QoL
–Is the part of a person’s overall quality of life that represents the functional effect of an illness and its consequent therapy upon a patient, as perceived by the patient
-
health
•a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity
-
chronic disease activity, detect undiagnosed/undetected disease
What are potential uses for HRQoL? (2)
-
QALYs; CUA
HRQoL can be used to derive utilities such as _______ & ______.
-
higher
Patients with the disease tend to give _______ utility scores than others.
-
a,c
When should we conduct CUAs?
a) when HRQoL is most important outcome
b) when intermediate outcomes are measured
c) when morbidity & mortality are important
d) when outcomes are measured by a single, natural unit
-
b,c
When should we NOT conduct CUAs?
a) when programs being evaluated have a wide range of outcomes
b) when intermediate outcomes are measured
c) when alternatives are equivalent in outcome measures
d) when analyzing how Alopecia affects a patient psychologically
-
c
Which pharmacoecon analysis expresses outcomes in $$?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
a
Which pharmacoecon analysis doesn't provide outcomes, just costs?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
e
Which pharmacoecon analysis is used to compare among different healthcare interventions?
a) Cost of Illness (COI)
b) Cost-Minimization Analysis (CMA)
c) Cost-Benefit Analysis (CBA)
d) Cost- Effective Analysis (CEA)
e) Cost-Utility Analysis (CUA)
-
determining utility is difficult; QALY and CUA are not well understood
What are disadvantages associated with CUA? (2)
-
future direct/non-direct medical cost avoided, increase productivity and avoid death (indirect), intangible benefits
What are 3 categories of benefits in a Cost-Benefit Analysis ?
-
utility
–Is a quantitative expression of an individual’s preference for, or desirability of, a particular state of health under conditions of uncertainty
